Working… Menu

Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01822080
Recruitment Status : Completed
First Posted : April 2, 2013
Last Update Posted : November 25, 2015
Information provided by (Responsible Party):

Brief Summary:

This study is aimed to evaluate efficacy and safety of dienogest 2 mg oral tablets in the treatment of endometriosis.

There will be 2 study phases: a double-blind, randomized, placebo-controlled, parallel-group phase over 24 weeks, and an open-label extension phase with 2 mg DNG daily p.o. over 28 weeks for all subjects who completed the double-blind phase, irrespective of their treatment assignment in the first study phase.

Condition or disease Intervention/treatment Phase
Endometriosis Drug: Dienogest (Visanne, BAY86-5258) Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter Study to Investigate the Efficacy and Safety of Daily Oral Administration of 2 mg Dienogest Tablets (Visanne/SH T00660AA) for the Treatment of Endometriosis in Chinese Patients: a Double-blind, Randomized, Placebo-controlled, Parallel Group Phase Over 24 Weeks Followed by an Open-label, Single-group Follow up Over 28 Weeks
Study Start Date : March 2013
Actual Primary Completion Date : April 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endometriosis
Drug Information available for: Dienogest

Arm Intervention/treatment
Experimental: Dienogest
50% of the participants will be randomized to this arm and will receive 2 mg dienogest (DNG) once daily by mouth from 0-52 weeks
Drug: Dienogest (Visanne, BAY86-5258)
2 mg dienogest (DNG) once daily by mouth

Placebo Comparator: Placebo
50% of the participants will be randomized to this arm and will receive placebo once daily by mouth from 0-24 weeks then switch to 2 mg dienogest (DNG) once daily by mouth from 25-52 weeks
Drug: Dienogest (Visanne, BAY86-5258)
2 mg dienogest (DNG) once daily by mouth

Drug: Placebo
Matching placebo once daily by mouth

Primary Outcome Measures :
  1. Change of endometriosis associated pelvic pain (EAPP) measured by visual analog scale (VAS) from baseline to 24 weeks [ Time Frame: 24 weeks after baseline ]

Secondary Outcome Measures :
  1. Percentage of treatment responders [ Time Frame: At 24 weeks ]
  2. Score on B&B (Biberoglu and Behrman severity profile for symptoms and findings) [ Time Frame: 24 weeks after baseline ]
  3. Quality of life assessed by patient questionnaire [ Time Frame: Up to 24 weeks ]
  4. Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: Up to 52 weeks ]
  5. Vaginal bleeding intensity recorded by patient diary and measured on a 5-point scale (none, spotting, light, normal, heavy) [ Time Frame: Up to 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women between 18 and 45 years of age, inclusive
  • Women with endometriosis confirmed by laparoscopy or laparotomy within ten years but no later than 2 weeks before the Screening Visit
  • A score of at least 30 on a 100 mm visual analog scale (VAS) for endometriosis-associated pelvic pain at Screening Visit and Baseline Visit
  • Good general health (except for findings related to endometriosis, with or without infertility), as evidenced by medical history and complete physical and gynecological examination
  • Willingness to use a barrier method of contraception is required

Exclusion Criteria:

  • Pregnancy or lactation (less than three months since delivery, abortion, or lactation before start of treatment)
  • Wish for pregnancy within intended treatment period
  • Before menarche or after menopause
  • Amenorrhea (more than three consecutive months in the six months before screening)
  • Undiagnosed abnormal genital bleeding
  • Previous/use of hormonal agents
  • Any disease or condition that may worsen under hormonal treatment
  • Signs and/or symptoms of therapy-resistant endometriosis despite more than one prior attempt at drug treatment or surgical therapy
  • Need for primary surgical treatment of endometriosis
  • Regular use of pain medication due to other underlying diseases
  • Contra-indication for the supportive analgesic medication (ibuprofen)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01822080

Layout table for location information
China, Guangdong
Guangzhou, Guangdong, China, 510120
China, Hebei
Shijiazhuang, Hebei, China, 050000
China, Hubei
Wuhan, Hubei, China, 430030
China, Hunan
Hengyang, Hunan, China, 421001
China, Jilin
Changchun, Jilin, China
China, Liaoning
Dalian, Liaoning, China, 116011
Shenyang, Liaoning, China, 110004
China, Shaanxi
Xi'an, Shaanxi, China, 710061
China, Sichuan
Chengdu, Sichuan, China, 610041
Chengdu, Sichuan, China, 610072
China, Zhejiang
Hangzhou, Zhejiang, China
Beijing, China, 100020
Beijing, China, 100026
Beijing, China, 100029
Beijing, China, 100032
Beijing, China, 100034
Beijing, China, 100038
Beijing, China, 100044
Beijing, China, 100083
Chongqing, China, 400010
Chongqing, China, 400016
Chongqing, China, 400042
Kunming, China
Shanghai, China, 200011
Shanghai, China, 200030
Shanghai, China, 200127
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT01822080    
Other Study ID Numbers: 13390
First Posted: April 2, 2013    Key Record Dates
Last Update Posted: November 25, 2015
Last Verified: November 2015
Keywords provided by Bayer:
Additional relevant MeSH terms:
Layout table for MeSH terms
Contraceptive Agents, Male
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral
Contraceptive Agents, Female
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents